Transcriptome Sequencing

Transcriptome sequencing, also known as RNA-seq, is a powerful addition to genetic testing. It has been reported to significantly enhance the diagnostic rate (by 7.5%–36%) depending on the clinical phenotype and tissue sample. RNA-seq aids in prioritizing and resolving VUS (Murdock et al, 2021; PMID: 33001864).

Multiple studies have shown the utility of functional studies such as RNA-seq in deciphering disease-causing non coding or synonymous splicing variants (PMID: 35946377; 35063693). For example, Wai et al (2020; PMID: 32123317) found that 33% of VUS alter splicing; this is significant since variants impacting splicing have a greater likelihood of being pathogenic.

Turnaround time is 8 weeks.

Who is this test for?

  • Patients who have had panel, exome, or genome sequencing and have one or more VUS that: i) are potentially causative of altered splicing, and ii) occur in a gene in which variation has been associated with the clinical presentation.
  • Research study samples
Alamya Health Logo

Advancing precision genomic medicine for all